Clinical Trial Update: T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating trastuzumab deruxtecan in combination with ramucirumab for HER2-low gastric or gastroesophageal junction adenocarcinoma is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Cyramza (ramucirumab)
• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: Yonsei University | Conditions: Gastric Cancer, Gastroesophageal Junction (GEJ) Cancer | Phase 1, Phase 2 | Status: RECRUITING